Several analysts have recently updated their ratings and price targets for Qiagen N.V. (NASDAQ: QGEN):

  • 11/9/2017 – Qiagen N.V. was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “QIAGEN ended the third quarter on a mixed note with earnings beating and revenues missing the Zacks Consensus Estimate. Declining HPV sales in the United States continue to be a drag. Competitive landscape and strong reliance on collaborations are other concerns. Over the last six months, QIAGEN has been trading below the broader industry. We are however, impressed with balanced growth across all of business segments. On the profitability front, QIAGEN performed well in terms of operating margin. We are also upbeat about the company’s partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio. Moreover, the company’s strategic focus to drive growth through Sample-to-Insight offerings buoys optimism. Moreover, QIAsymphony continued to progress toward the target of 2,000 cumulative placements by 2017-end.”
  • 11/8/2017 – Qiagen N.V. had its “buy” rating reaffirmed by analysts at Deutsche Bank AG.
  • 11/7/2017 – Qiagen N.V. had its “buy” rating reaffirmed by analysts at Commerzbank Ag.
  • 11/7/2017 – Qiagen N.V. was upgraded by analysts at TheStreet from a “c+” rating to a “b+” rating.
  • 11/7/2017 – Qiagen N.V. had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 11/3/2017 – Qiagen N.V. had its “hold” rating reaffirmed by analysts at Cowen and Company. They now have a $33.00 price target on the stock.
  • 10/16/2017 – Qiagen N.V. was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “QIAGEN’s commitment to return more to its shareholders through increased share repurchases reflects solid cash position. We are also upbeat about QIAGEN’s partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio. Moreover, the company’s strategic focus to drive growth through Sample to Insight offerings buoys optimism. QIAGEN is forming collaborations in the personalized homecare space also. Moreover, QIAsymphony continued to grow towards the target of 2,000 cumulative placements by 2017 end. On the flip side, over the last three months, QIAGEN has been trading below the broader industry. Moreover, adverse currency translation continues to be a drag on overall sales. Furthermore, declining HPV sales in the United States continues to be a drag. Competitive landscape and strong reliance on collaborations also continue to be concerns.”
  • 10/10/2017 – Qiagen N.V. was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $39.00 price target on the stock. According to Zacks, “QIAGEN’s commitment to return more to its shareholders through increased share repurchases reflects solid cash position. We are also upbeat about QIAGEN’s partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio. Moreover, the company’s strategic focus to drive growth through Sample to Insight offerings buoys optimism. QIAGEN is forming collaborations in the personalized homecare space also. Moreover, QIAsymphony continued to grow towards the target of 2,000 cumulative placements by 2017 end. On the flip side, over the last three months, QIAGEN has been trading below the broader industry. Moreover, adverse currency translation continues to be a drag on overall sales. Furthermore, declining HPV sales in the United States continues to be a drag. Competitive landscape and strong reliance on collaborations also continue to be concerns.”
  • 9/28/2017 – Qiagen N.V. had its “hold” rating reaffirmed by analysts at Cowen and Company. They now have a $33.00 price target on the stock.

Shares of Qiagen N.V. (NASDAQ:QGEN) opened at $30.68 on Thursday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.78 and a current ratio of 5.33. The company has a market cap of $7,005.11, a P/E ratio of 25.02, a price-to-earnings-growth ratio of 1.88 and a beta of 1.13. Qiagen N.V. has a fifty-two week low of $27.51 and a fifty-two week high of $36.34.

Qiagen N.V. (NASDAQ:QGEN) last announced its earnings results on Monday, November 6th. The company reported $0.32 EPS for the quarter, hitting the consensus estimate of $0.32. The firm had revenue of $364.00 million for the quarter, compared to the consensus estimate of $363.42 million. Qiagen N.V. had a net margin of 6.40% and a return on equity of 11.36%. The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period last year, the company posted $0.29 EPS. equities analysts anticipate that Qiagen N.V. will post 1.25 earnings per share for the current fiscal year.

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.